ArticleInternational journal of hematology2017

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.

Shinsuke Iida et al.PubMed ↗Publisher ↗

No numbers read from the abstract.